Payment overview · 2025
General Payments
$65.38
4 reported records · 3 companies
Healthcare provider profile · identity verified
David O. Degear, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NEW RICHMOND, WI · NPI 1144202425
Verified facts
What the public records show
CMS Open Payments records show David O. Degear, M.D. received $65.38 in general payments during 2025 across 4 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 51.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.61 | 51.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.65 | 25.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.12 | 23.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $65.38 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 689 | 171 |
| Gabapentin | Gabapentin | 512 | 96 |
| Lisinopril | Lisinopril | 444 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 438 | 110 |
| Metoprolol Succinate | Metoprolol Succinate | 361 | 85 |
| Omeprazole | Omeprazole | 336 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 335 | 67 |
| Simvastatin | Simvastatin | 307 | 72 |
| Losartan Potassium | Losartan Potassium | 303 | 87 |
| Furosemide | Furosemide | 282 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 65 |
| Warfarin Sodium | Warfarin Sodium | 238 | 49 |
| Trazodone Hcl | Trazodone Hcl | 212 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 202 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 197 | 40 |
| Glipizide Er | Glipizide | 175 | 47 |
| Metformin Hcl | Metformin Hcl | 167 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 56 |
| Potassium Chloride | Potassium Chloride | 145 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 38 |
| Metformin Hcl Er | Metformin Hcl | 129 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 35 |
| Allopurinol | Allopurinol | 125 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 35 |
| Sertraline Hcl | Sertraline Hcl | 114 | 35 |
| Oxycodone Hcl | Oxycodone Hcl | 109 | 20 |
| Meloxicam | Meloxicam | 108 | 30 |
| Eliquis | Apixaban | 95 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 21 |
| Tramadol Hcl | Tramadol Hcl | 85 | 18 |
| Lorazepam | Lorazepam | 83 | 14 |
| Donepezil Hcl | Donepezil Hcl | 82 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 21 |
| Carvedilol | Carvedilol | 76 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 73 | 16 |
| Baclofen | Baclofen | 70 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 22 |
| Montelukast Sodium | Montelukast Sodium | 66 | 16 |
| Finasteride | Finasteride | 62 | 14 |
| Jardiance | Empagliflozin | 62 | 15 |
| Ibuprofen | Ibuprofen | 61 | 16 |
| Methocarbamol | Methocarbamol | 60 | 12 |
| Atenolol | Atenolol | 58 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 58 | 11 |
| Alprazolam | Alprazolam | 57 | suppressed |
| Trulicity | Dulaglutide | 56 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 17 |
| Pregabalin | Pregabalin | 55 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 55 | 17 |
| Buspirone Hcl | Buspirone Hcl | 53 | suppressed |
| Prednisone | Prednisone | 53 | 28 |
| Cephalexin | Cephalexin | 52 | 28 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 51 | 15 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Celecoxib | Celecoxib | 47 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 46 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 45 | 11 |
| Mirtazapine | Mirtazapine | 45 | 16 |
| Ozempic | Semaglutide | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 40 | 11 |
| Famotidine | Famotidine | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 35 | suppressed |
| Gemfibrozil | Gemfibrozil | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Carisoprodol | Carisoprodol | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Naproxen | Naproxen | 30 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 12 |
| Latanoprost | Latanoprost | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Loperamide | Loperamide Hcl | 26 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 12 |
| Linzess | Linaclotide | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 14 |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Calcipotriene | Calcipotriene | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Felbamate | Felbamate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $65.38 · 4 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, JARDIANCE, LEQVIO | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error